Replies to post #23188 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

the update on 113 was the most significant part of the presentation

The fact that they are planning to start the ALK+ pivotal trial in 2013 without waiting for the continuing Phase 1/2 cohort data speaks volumes.